Jupiter Neurosciences licenses MDMA-based drug ALA-002 for up to $100M Jul 21, 2026 07:13AM
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million Jul 21, 2026 07:13AM
Jupiter Neurosciences secures $100M term sheet for MDMA therapeutic rights May 20, 2026 07:44AM
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech May 20, 2026 07:38AM